Search trials



Primary RegistryProtocol numberPublic titleScientific titleType of studyRecruitment statusLast updated
LBCTR2023115474LAU.SOP.HM3.13/Sep/2023“Surgical Site Infections Occurrence and Associated Risk Factors: a Matched Case-Control Study”“Surgical Site Infections Occurrence and Associated Risk Factors: a Matched Case-Control Study”ObservationalRecruiting28/11/2023
LBCTR2024015480NN7533-4470ACENT 1A multicentre trial evaluating the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell diseaseInterventionalPending01/02/2024
LBCTR2024015481ML44926LUNG StudyA Biomarker-Driven Precision Management of Lebanese Patients with Previously Untreated Metastatic Non-Squamous Non-Small Cell LunG CancerInterventionalPending19/08/2024
LBCTR2023125487LAU.SOP.ER1.14/Sep/2022Pharmacist-Led Medication Reconciliation Upon Discharge from the Orthopedic Surgery DepartmentPharmacist-Led Medication Reconciliation Upon Discharge from the Orthopedic Surgery Department: An Interventional Randomized Controlled TrialInterventionalComplete19/12/2023
LBCTR2019121368CINC280A2201Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung CancerA Phase II, Multicenter Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) InterventionalComplete25/12/2019
LBCTR2019060241CLEE011A3201CStudy to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer ( Right Choice)A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients With Hormone Receptor-positive/ HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer InterventionalComplete03/06/2019
LBCTR2019010167CNTO1959CRD3001A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's DiseaseA Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's DiseaseInterventionalComplete24/10/2018
LBCTR2020043405APD334-301Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative ColitisA Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative ColitisInterventionalComplete25/02/2020
LBCTR2020043427APD334-302Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative ColitisA Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative ColitisInterventionalComplete08/03/2020
LBCTR2022125201KOR-PED-201Single dose study to evaluate how intravenous administered difelikefalin is absorbed by and cleared from Adolescents on HaemodialysisAn Open-label, Single Arm Study to Evaluate the Pharmacokinetics of a Single Dose of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on HaemodialysisInterventionalComplete21/11/2022
items per page121 - 130 of 179 items